This session explores the intersection of mental health, stigma, and innovative care models in chronic liver disease. Presenters will share research and strategies aimed at improving quality of life and clinical outcomes through patient education, timely interventions, and integrated, value-based care.
Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.
The therapeutic options for patients with hepatobiliary cancers are expanding, and at the same time the impact of comorbidities on outcomes has become clearer. Participants will learn about the influence of MASLD, tumor buden and liver heatlh on treatment success; the potential of immuotherapy in HCC; and consider surgical treatment options in hepatobiliary cancers.
This session will feature translational and early-phase clinical studies that are advancing the therapeutic landscape for chronic hepatitis B. Highlights include a novel capsid assembly modulator, early stage HBV immune modulation trial, therapeutic vaccines, antisense oligonucleotides in combination with pegylated interferon, and a preclinical study of an epigenetic editing agent demonstrating HBV surface antigen loss through targeted DNA methylation. Together, these studies showcase innovative pathways toward viral suppression and functional cure.<br />
Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.
The abstracts presented in this session advance our understanding of alcohol-associated liver disease (ALD) through cutting-edge research utilizing both mouse and human models. The session highlights key mechanisms and mediators of ALD, including oxidative stress, inflammation, and the gut-liver axis. It also explores the interplay between the liver and adipose tissue, the impact of environmental factors, and the potential of GLP1 as a therapeutic target. The objective is to foster discussion and collaboration around these diverse yet interconnected pathways to inform future research and treatment strategies.
Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.
This session will examine the intersection of chronic hepatitis B with metabolic risk factors, pharmacologic exposures, and evolving biomarkers in liver disease progression and surveillance. Topics will include the protective association of statins with HCC risk, the impact of hepatitis B on fibrosis in MASLD and the impact of GLP-1 on outcomes in HBV. Additional talks will address the potential for HBsAg quantification to define thresholds for discontinuing HCC surveillance and global progress toward HBV elimination targets.
This abstract parallel session features a series of reports on the exploration of new agents in AIH and PBC, along with intriguing data on enhanced monitoring in cholestatic disorders.
Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.